Literature DB >> 20567822

CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection.

Noriyuki Yamada1, Satoshi Oizumi, Eiki Kikuchi, Naofumi Shinagawa, Jun Konishi-Sakakibara, Atsushi Ishimine, Keisuke Aoe, Kenichi Gemba, Takumi Kishimoto, Toshihiko Torigoe, Masaharu Nishimura.   

Abstract

Defects in human leukocyte antigen (HLA) class I expression may allow tumor cells to escape immune recognition. T cell infiltration is associated with a good prognosis in many cancers. However, the role of HLA class I expression and tumor-infiltrating lymphocytes (TILs) in malignant pleural mesothelioma (MPM) has not been fully analyzed. In the present study, we investigated the immune profiles and conducted outcome analyses of MPM patients. HLA class I expression and TILs (CD4(+), CD8(+), and NK cells) were detected by immunohistochemistry in a series of 44 MPM cases. To detect HLA class I expression, specimens were stained with the anti-pan HLA class I monoclonal antibody EMR8-5. The expression of HLA class I was positive in all patients. There was no case that showed negative HLA class I expression. The density of CD4(+) and CD8(+) TILs were strongly correlated (R = 0.76, p < 0.001). A high density of CD8(+) TILs was a significantly better prognostic factor for the survival of patients with extrapleural pneumonectomy (p < 0.05). Multivariate analysis revealed that a high density of CD8(+) TILs is an independent prognostic factor for patients who underwent extrapleural pneumonectomy. The presence of intratumoral CD8(+) T cells was correlated with an improved clinical outcome, raising the possibility that CD8(+) T cells might play a pivotal role in the antitumor immune response against MPMs. Thus, the stimulation of CD8(+) lymphocytes might be an efficacious immunotherapy for MPM patients.

Entities:  

Mesh:

Year:  2010        PMID: 20567822     DOI: 10.1007/s00262-010-0881-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  81 in total

Review 1.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

2.  High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer.

Authors:  Ryan O Emerson; Anna M Sherwood; Mark J Rieder; Jamie Guenthoer; David W Williamson; Christopher S Carlson; Charles W Drescher; Muneesh Tewari; Jason H Bielas; Harlan S Robins
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

3.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma.

Authors:  Elly Marcq; Vasiliki Siozopoulou; Jorrit De Waele; Jonas van Audenaerde; Karen Zwaenepoel; Eva Santermans; Niel Hens; Patrick Pauwels; Jan P van Meerbeeck; Evelien L J Smits
Journal:  Oncoimmunology       Date:  2016-11-28       Impact factor: 8.110

5.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

Review 6.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

7.  Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.

Authors:  Hong Qiu; Patrick M Zmina; Alex Y Huang; David Askew; Barbara Bedogni
Journal:  Cancer Lett       Date:  2018-07-21       Impact factor: 8.679

8.  Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade.

Authors:  Mohammad Rashidian; Martin W LaFleur; Vincent L Verschoor; Anushka Dongre; Yun Zhang; Thao H Nguyen; Stephen Kolifrath; Amir R Aref; Christie J Lau; Cloud P Paweletz; Xia Bu; Gordon J Freeman; M Inmaculada Barrasa; Robert A Weinberg; Arlene H Sharpe; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

9.  Combination immune checkpoint blockade as an effective therapy for mesothelioma.

Authors:  Vanessa S Fear; Caitlin Tilsed; Jonathan Chee; Catherine A Forbes; Thomas Casey; Jessica N Solin; Sally M Lansley; William Joost Lesterhuis; Ian M Dick; Anna K Nowak; Bruce W Robinson; Richard A Lake; Scott A Fisher
Journal:  Oncoimmunology       Date:  2018-07-30       Impact factor: 8.110

Review 10.  Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccines.

Authors:  Jeanne Menez-Jamet; Catherine Gallou; Aude Rougeot; Kostas Kosmatopoulos
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.